Skip to main content
SYBX
OTC Life Sciences

Synlogic Reports Q1 Results: Cash Balance Exceeds Market Cap Amid Strategic Review

Analysis by Arik Shkolnikov
Sentiment info
Neutral
Importance info
8
Price
$0.647
Mkt Cap
$7.569M
52W Low
$0.54
52W High
$1.96
Market data snapshot near publication time

summarizeSummary

Synlogic's Q1 2026 report shows a cash balance of $14.1 million, significantly higher than its $7.57 million market cap, as it continues to operate as a delisted shell company exploring strategic alternatives.


check_boxKey Events

  • Cash Balance Exceeds Market Cap

    The company reported $14.1 million in cash and cash equivalents as of March 31, 2026, which is nearly double its current market capitalization of $7.57 million. This translates to approximately $1.20 in cash per share, significantly above the current stock price of $0.647 and a recent buyout offer of $0.64 per share.

  • Q1 Net Income Driven by Non-Cash Gain

    Net income for Q1 2026 was $0.7 million, primarily due to a $1.9 million non-cash gain from the revaluation of purchase warrant liabilities. This gain offset an increased operational loss of $1.3 million for the quarter.

  • Cash Runway Confirmed Amid Strategic Review

    Despite being a delisted public shell company, Synlogic projects its current cash and cash equivalents will be sufficient to fund operations for at least the next 12 months as it continues to evaluate strategic alternatives, including a potential merger or sale.

  • Ongoing Material Weakness in Internal Controls

    Management disclosed that a material weakness in internal control over financial reporting, previously identified in the 2025 Annual Report, continues to be present as of March 31, 2026.


auto_awesomeAnalysis

Synlogic's Q1 2026 financial report highlights a significant cash position of $14.1 million, which is nearly double its current market capitalization of $7.57 million. While the company reported a net income of $0.7 million, this was primarily driven by a non-cash gain of $1.9 million from the revaluation of warrant liabilities, as operational losses increased to $1.3 million. The company, which is a delisted public shell, confirms it has sufficient cash to fund operations for at least the next 12 months as it continues to explore strategic alternatives, including a potential merger or sale. The ongoing material weakness in internal controls remains a concern. This financial update provides critical context for investors evaluating the company's intrinsic value against its market valuation and the recent buyout offer.

At the time of this filing, SYBX was trading at $0.65 on OTC in the Life Sciences sector, with a market capitalization of approximately $7.6M. The 52-week trading range was $0.54 to $1.96. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed SYBX - Latest Insights

SYBX
May 14, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
SYBX
Apr 06, 2026, 4:15 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
SYBX
Mar 12, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
9
SYBX
Jan 29, 2026, 9:00 AM EST
Filing Type: 8-K/A
Importance Score:
9
SYBX
Jan 20, 2026, 9:00 AM EST
Filing Type: 8-K
Importance Score:
9